Higher daytime light exposure was associated with a significantly lower risk of developing dementia, while nighttime light exposure showed no significant relationship. In this study of 87,577 dementia-free UK adults (average age 62 years) followed for a median of 8.1 years, 741 participants developed dementia. Researchers measured light exposure using wrist-worn devices over seven days and found that exposure to daytime light levels above 1,000 lux was associated with a 16% lower risk of dementia. Spending at least 0.7 hours per day in bright light (≥5,000 lux) was linked to an even greater risk reduction of about 17%. Exploratory analyses suggested that healthier circadian rest–activity rhythms and favorable brain structural changes may explain up to one-third of this protective association. The benefits of daytime light exposure were particularly strong among high risk individuals with high nighttime light exposure, an evening chronotype (night owl), or the APOE ε4 genetic risk variant, with dementia risk reductions reaching as much as 41%. Notably, insufficient bright daytime light exposure (<0.7 hours/day) predicted dementia risk more strongly than several established risk factors, including obesity, alcohol consumption, and traumatic brain injury. These findings suggest that increasing exposure to natural daylight may represent a simple, low-cost strategy for supporting long-term brain health and reducing dementia risk. Source: https://onlinelibrary.wiley.com/
Accelerated biological aging was associated with a higher risk of early-onset solid cancers in young…
Men who started testosterone therapy (TT) without evidence of hypogonadism had significantly higher long-term risks…
A secondary MRI analysis of the US POINTER randomized clinical trial found that a structured…
Dementia risk factors vary substantially across countries, but they frequently cluster together in similar patterns…
A systematic review and network meta-analysis of 262 randomized trials involving 99,791 participants found that…
Approximately 21% of patients with phenotypically mild hypertrophic cardiomyopathy (HCM) experienced major adverse cardiovascular events…
This website uses cookies.